Media OutReach
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
- UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
- In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
- UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.
GUANGDONG, CHINA & BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 February 2026 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G).
UBT251 is being jointly developed by TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology) and Novo Nordisk under an agreement signed in March 2025. United Biotechnology is responsible for development in Chinese mainland, Hong Kong, Macau and Taiwan, while Novo Nordisk is responsible for development in the rest of the world.
The trial, conducted by United Biotechnology, investigated the safety and efficacy of once-weekly injectable 2 mg, 4 mg and 6 mg doses of UBT251 compared to placebo in Chinese people with overweight or obesity. From a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7% (-17.5 kg) compared to 2.0% (-1.6kg) in the placebo group after 24 weeks of treatment[i].
Moreover, all dose groups of UBT251 showed statistically significant improvements relative to placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure and lipids.
In the trial, UBT251 appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with incretin-based therapies.
“The success of the phase 2 clinical trial of UBT251 in China represents another significant milestone in TUL’s innovation-driven development,” said Mr Tsoi Hoi Shan, Chairman of TUL. “We will continue to focus on chronic diseases, including endocrine and metabolic disorders, accelerate the further development of UBT251, and strive to bring more high-quality treatment options to patients worldwide at the earliest opportunity.”
“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development at Novo Nordisk. “We look forward to reporting data from a global trial with UBT251 conducted by Novo Nordisk next year.”
Novo Nordisk recently initiated a global phase 1b/2a trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of UBT251 for up to 28 weeks in around 330 people living with overweight or obesity. Topline data from that trial is expected in 2027. Novo Nordisk also expects to initiate a phase 2 trial with UBT251 in people with type 2 diabetes in the second half of 2026.
United Biotechnology will present detailed data from the Chinese phase 2 trial at a medical congress later this year. Based on the results of this trial, the company is planning to initiate a phase 3 trial in Chinese patients with overweight or obesity.
About the Chinese phase 2 trial
This randomized, double-blind, placebo-controlled trial enrolled a total of 205 Chinese patients with obesity (BMI ≥ 28.0 kg/m²) or overweight (24.0 kg/m² ≤ BMI < 28.0 kg/m²) with at least one weight-related comorbidity. The baseline mean body weight of the patients was 92.2 kg, with a baseline mean BMI of 33.1 kg/m².
Patients were randomly assigned to receive weekly subcutaneous injections of UBT251 in doses of 2 mg, 4 mg, 6 mg, or placebo for 24 weeks.
The primary endpoint of the trial was the percentage change in body weight from baseline after 24 weeks of treatment.
About UBT251
UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.
In March 2025, United Biotechnology entered an exclusive license agreement with Novo Nordisk A/S for UBT251. Under the agreement, Novo Nordisk obtained exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialise UBT251. United Biotechnology retained the rights for UBT251 in Chinese mainland, Hong Kong, Macau and Taiwan.
Hashtag: #UBT251
The issuer is solely responsible for the content of this announcement.
About TUL and United Biotechnology
Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine, finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit www.tul.com.cn.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, YouTube.
Asia’s first Design & Innovation Festival announces its venue and key speakers — where Japanese design expertise meets the cultural diversity of Asia
| Name | SYNC Design & Innovation in SITE 2026 |
| Date | Friday, June 26, 2026 |
| Venue | Paragon Hall, 5th Floor, Siam Paragon, Bangkok, Thailand |
| Admission | Free (advance registration required) |
| Languages | Thai / English / Japanese |
| Website | https://syncforum.asia |
| Organizer | Nikkei Business Publications, Inc. |
| Production & Co-organizers | FOURDIGIT Inc., National Innovation Agency (NIA), Thailand |
| Supported by | Creative Economy Agency (CEA) |
| Production partners | Y’s Connection Inc., J-WAVE, Inc., iDID |
Hashtag: #FOURDIGIT
The issuer is solely responsible for the content of this announcement.
Code4Mzansi highlights the growing strength of South Africa’s developer ecosystem and the role of youth-led innovation in shaping the country’s digital future
JOHANNESBURG, SOUTH AFRICA – Media OutReach Newswire – 26 May 2026 – South Africa’s emerging developers are building close to the ground, with many of the strongest solutions at the inaugural Huawei Code4Mzansi finals focused on systems people use every day: township retail, healthcare, energy, agriculture, payments and the creative economy.
The competition was held in partnership with the Department of Small Business Development. “The Code4Mzansi competition is not just a celebration of achievement, it is a launchpad for the future,” said Minister Stella Ndabeni, whose department co-hosted the event and delivered the closing address.
The finals revealed a clear shift from building abstract digital products to practical tools that help small businesses trade better, communities access services more easily, and local industries solve problems faster.
Four finalist teams focused directly on the township economy, with solutions covering food safety verification for spaza shops, offline point-of-sale systems built for load-shedding, WhatsApp-native marketplaces for informal retailers, and community credit systems for SASSA grant recipients.
Others addressed AI-driven healthcare access, electricity theft detection, smart agriculture, financial infrastructure for the creator economy, and AI-generated African music.
Held at Huawei Office Park in Woodmead, the finals brought together more than 100 attendees, including government representatives, academic partners, industry leaders and media.
“The quality of the finalist solutions demonstrated the potential of local innovation to respond to real market needs,” said Steven Chen, Cloud CEO of Huawei Technologies South Africa.
Academic partners included the University of Pretoria, the University of Johannesburg, the University of the Witwatersrand and the University of Cape Town.
“Small businesses are the backbone of our economy, and technology is their greatest accelerator. The participants here today are future entrepreneurs who will drive South Africa’s digital economy forward,” said Professor Thokozani Shongwe, Vice Dean of Postgraduate Studies, Research and Internationalisation at the University of Johannesburg’s Faculty of Engineering and the Built Environment.
Industry partner rain also attended. Leon Nortje, Principal and Senior Architect at rain, said the competition offered a strong view of the country’s emerging technology pipeline.
“It is always good to see new projects and new teams working on solutions that are valuable and industry-related. We will be looking out for potential new employees,” said Nortje.
The winners
The finalists competed for a prize pool of R800,000. MAAT by SIMVAK was named the overall grand winner and received the Business Value Award, taking home R300,000. The platform addresses food safety and regulatory compliance in South Africa’s informal retail sector through AI agents, real-time product recall alerts, and counterfeit detection for the spaza shop ecosystem.
“The spaza network is the supply chain for most South African households,” said SIMVAK founder Shingirayi Mandebvu.
HealthHive by FTCK received second prize in the Business Value Award category, taking home R200,000, for its AI telemedicine platform that matches patients with the right medical practitioners based on their symptoms.
Auraa received the Grand Innovation Award for its AI music engine built to generate authentic African sound. The platform has been associated with an album that has crossed one million streams.
The Future Star Award went to e-Khadi, a community credit and stokvel platform giving SASSA grant recipients access to essentials at their local spaza shops, supported by AI-assisted credit scoring and fraud detection.
The People’s Choice Award, voted by the public on Huawei’s social media channels, went to DevRift, a semi-finalist in the competition, who took home R100,000.
Minister Ndabeni delivered the closing address, positioning Code4Mzansi within the government’s agenda for youth entrepreneurship, small business development and digital inclusion.
“Our task is to ensure that innovation does not remain a moment of applause, but becomes a pathway to enterprise creation, digital inclusion, and sustainable growth,” she said.
“Thank you to Huawei for being a perfect partner on the journey that we are travelling, and of course, those that matter most, the developers who dared to compete,” she said.
Code4Mzansi forms part of the global Huawei Cloud Developer Competition. In its inaugural edition, South Africa attracted more participants than any other country: 1,041 across 353 teams, including 176 enterprise teams, resulting in the highest enterprise participation rate among all competing markets. Twenty semi-finalists were selected before the top nine advanced to the final.
For the finalists, the work is just beginning. As Minister Ndabeni said, “Go home today proud. But tomorrow, wake up, build again.”
Hashtag: #Huawei #Code4Mzansi #SouthAfrica
https://www.huawei.com/za/
https://www.linkedin.com/company/Huawei
https://twitter.com/HuaweiSAR
https://www.facebook.com/HuaweiSARhttp://www.google.com/+Huawei
http://www.youtube.com/Huawei
The issuer is solely responsible for the content of this announcement.
About Huawei
Founded in 1987, Huawei is a leading global provider of information and communications technology (ICT) infrastructure and smart devices. With 213,000 employees operating in over 170 countries, we serve more than three billion people worldwide.
Huawei is committed to bringing digital to every person, home, and organisation for a fully connected, intelligent world. In 2025, Huawei generated CNY880.9 billion in revenue, reinvesting 21.8% (CNY192.3 billion) into R&D, with about 53.7% of its employees working in R&D. As a private company fully owned by its employees, Huawei focuses on customer-centric innovation and open collaboration to create lasting value and drive technological breakthroughs globally.
For more information, please visit Huawei online at www.huawei.com or follow us on:
http://www.huawei.com/za/
https://twitter.com/HuaweiSAR
https://www.facebook.com/HuaweiSAR
http://www.linkedin.com/company/Huawei
http://www.google.com/+Huawei
http://www.youtube.com/Huawei
Congratulating Dr Lai on her achievement, John Lee, Chief Executive of the Hong Kong Special Administrative Region (HKSAR), said that the HKSAR can “transform from a ‘supporter’ of the country’s great aerospace endeavours into an ‘executor’ “.
“This not only demonstrates the HKSAR’s capability in contributing to the country’s development into an aerospace power, but also showcases how Hong Kong could better integrate into and serve the overall national development,” Mr Lee said.
“This mission is of great significance, as it is not only the first manned spaceflight mission during the 15th Five-Year Plan period, but also the first time for a payload expert from the HKSAR to participate in it.”
The Shenzhou-23 crew will conduct on-orbit rotation with the Shenzhou-21 crew. The crew, including Dr Lai, will stay in the space station and conduct multiple experiments and applications in various fields such as scientific applications.
The Secretary for Innovation, Technology and Industry of the HKSAR Government, Professor Sun Dong, led a delegation to the Jiuquan Satellite Launch Center to witness this historic moment. Members of the delegation included other government representatives, I&T experts, youths and students.
“I truly believe this is a great demonstration of Hong Kong integrating into and serving the overall national development through concrete actions, while contributing our strength in I&T,” Professor Sun said.
” ‘Science and technology is primary productive force, talent is primary resource, and innovation is primary driver of growth.’ The HKSAR Government will continue to drive the development of I&T, accelerate the establishment of an international I&T centre, and make greater contributions to building our nation into a strong power in science, technology, and aerospace.”
Commissioner for Innovation and Technology of the HKSAR Government, Mr Ivan Lee, said that the Government had been providing funding support for universities and research institutions in conducting aerospace technology-related projects through the Innovation and Technology Fund.
“In 2024, we launched a special call for funding applications, inviting universities to submit project proposals related to aerospace technology. Following a selection process, we supported six projects. Among them was the Multi‑Spectral Imaging Carbon Observatory (MUSICO) developed by a team from the Hong Kong University of Science and Technology,” he said.
On the Tiangong Space Station, Dr Lai will conduct experiments including operating the MUSICO — the world’s first lightweight, high-resolution synergistic observatory for carbon dioxide and methane emission point sources.
Born and raised in Hong Kong, Dr Lai is a Superintendent of the Hong Kong Police Force. In the recruitment exercise of China’s fourth batch of preparatory astronauts launched in 2022, she was successfully selected as a payload expert and was deployed to the China Astronaut Research and Training Center for training.
Before embarking on the historic spaceflight, Dr Lai expressed hope that it would inspire more Hong Kong youths to devote themselves to the field of I&T, thereby contributing to the country’s scientific and technological self-reliance and strength.
Hashtag: #HongKong #BrandHongKong #I&T #aerospace #technology
https://www.brandhk.gov.hk/
https://www.linkedin.com/company/brand-hong-kong/
https://x.com/Brand_HK/
https://www.facebook.com/brandhk.isd
https://www.instagram.com/brandhongkong
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn